Junhui Ye

Peking University

H指数:14

被引数:913

个人简介

暂无内容

教育背景

暂无内容

工作经历

暂无内容

荣誉奖项

暂无内容

Anlotinib plus oral fluoropyrimidine S-1 in refractory or relapsed small-cell lung cancer (SALTER TRIAL): a multicenter, single-arm, phase II trial

BMC CANCER

IF3.4

2024-09-271

OAAI

RETRACTION: MicroRNA-671-5p inhibits cell proliferation, migration and invasion in non-small cell lung cancer by targeting MFAP3L (Retraction of Vol 25, art no 30, 2022)

MOLECULAR MEDICINE REPORTS

IF3.5

2024-04-150

OAAI

MicroRNA-671-5p inhibits cell proliferation, migration and invasion in non-small cell lung cancer by targeting MFAP3L

MOLECULAR MEDICINE REPORTS

IF3.5

2021-11-2813

Seawater-Associated Highly Pathogenic Francisella hispaniensis Infections Causing Multiple Organ Failure

EMERGING INFECTIOUS DISEASES

IF6.6

2020-10-017

OAAI

Dynamics of Plasma EGFR T790M Mutation in Advanced NSCLC: A Multicenter Study

TARGETED ONCOLOGY

IF4

2019-11-063

PREAI

Yang, Zhengquan; Li, Jialu; Hu, Yujie; Chen, Meihua; Peng, Danli; Zong, Dan; Shang, Qingjuan; Tao, Lianqin; Zhao, Yanling; Ni, Yiyun; Ye, Jinyan; Xie, Yupeng; Yang, Li; Lin, Quan; Cai, Chang; Xu, Ning; Huang, Xiaoping; Dong, Xiaoting; Zhou, Zhonghui; Yu, Yali; Shangguan, Zongxiao; Xu, Yangyang; Ying, Weiping; Weng, Meiling; Yuan, Zuguo; Dong, Zhijun; Li, Jifa; Zheng, Zhe; Pan, Jiongwei; Liu, Lu; Ye, Junhui; Zhang, Zhan; Li, Wenfeng; Zhu, Junfei; Jin, Shengnan; Li, Yuping; Ding, Chunming

ROS1-ADGRG6: a case report of a novel ROS1 oncogenic fusion variant in lung adenocarcinoma and the response to crizotinib

ROS1-ADGRG6: 肺腺癌中一种新型ROS1致癌融合变异体的病例报告和对克唑替尼的反应

BMC CANCER

IF3.4

2019-08-0515

OAAI

One-pot synthesize Al-doped α-Ni(OH)2/reduced graphene oxide composite for high-performance asymmetric supercapacitors

JOURNAL OF ALLOYS AND COMPOUNDS

IF6.3

2019-08-0120

PREAI

A response prediction model for taxane, cisplatin, and 5-fluorouracil chemotherapy in hypopharyngeal carcinoma